etx-dif_hormone-ch6-fig10

Figure 10. PFS of patients that received Lanreotide in the core and OLE CLARINET study. The OLE data is only visualized for patients that were originally assigned to and continued the Lanreotide treatment. This figure was retrieved and adapted from Endocrine-related cancer, Caplin M. E., Pavel M., Cwikla J. B., et al., Anti-tumor effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study, 23 (3): 191-9 © 2016 (190).